Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 10, 2011, Pages 2323-2329

  Tagliabue, C ^a   Techasaensiri, C ^b   Torres, J P ^b   Katz, K ^b   Meek, C ^c   Kannan, T R ^d   Coalson, J J ^d   Esposito, S ^a   Principi, N ^a   Leff, R ^c   Baseman, J B ^d   Hardy, R D ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e ID Specialists (Adult and Pediatric)   (United States)

Author keywords

Asthma; Cytokines; Macrolides; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CLARITHROMYCIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; PLACEBO;

AIRWAY HYPERRESPONSIVENESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPERIMENTAL MOUSE; FEMALE; HISTOPATHOLOGY; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOPLASMA PNEUMONIA; NONHUMAN; QUANTITATIVE ANALYSIS; RESPIRATORY TRACT DISEASE;

ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINES; CLARITHROMYCIN; CYTOKINES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA;

EID: 80052902453     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr306     Document Type: Article

References (29)

1. McCracken GH Jr. Current status of antibiotic treatment for Mycoplasma pneumoniae infections. Pediatr Infect Dis J 1986; 5: 167-71.
2. Shames JM, George RB, Holliday WB et al. Comparison of antibiotics in the treatment of mycoplasmal pneumonia. Arch Intern Med 1970; 125: 680-4.
3. Hardy RD. Mycoplasma infections. In: Dale DC, Federman DD, eds. ACP Medicine. New York: American College of Physicians, 2009; 1-11.
4. Principi N, Esposito S, Blasi F et al. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis 2001; 32: 1281-9.
5. Nilsson AC, Björkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol 2008; 8: 93.
6. Tessier PR, Kim MK, Zhou W et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002; 46: 1425-34.
7. Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004; 10: 3045-53.
8. Hardy RD, Rios AM, Chavez-Bueno S et al. Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Chemother 2003; 47: 1614-20.
9. Fonseca-Aten M, Salvatore CM, Mejías A et al. Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 2005; 49: 4128-36.
10. Ríos AM, Fonseca-Aten M, Mejías A et al. Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 2005; 49: 3970-3.
11. Fonseca-Aten M, Rios AM, Mejias A et al. Treatment of experimental chronic pulmonary mycoplasmosis. Int J Antimicrob Agents 2006; 28: 253-8.
12. Salvatore CM, Fonseca-Aten M, Katz-Gaynor K et al. Intranasal interleukin-12 therapy inhibits Mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumonia. Infect Immun 2008; 76: 732-8.
13. Salvatore CM, Techasaensiri C, Tagliabue C et al. Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 2009; 53: 1546-51.
14. Tagliabue C, Salvatore CM, Techasaensiri C et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2008; 198: 1180-8.
15. Ríos AM, Mejías A, Chávez-Bueno S et al. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob Agents Chemother 2004; 48: 2897-904.
16. Cimolai N, Taylor GP, Mah D et al. Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection. Microbiol Immunol 1992; 36: 465-78.
17. Gonzalo JA, Lloyd CM, Wen D et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998; 188: 157-67.
18. Hamelmann E, Schwarze J, Takeda K et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997; 156: 766-75.
19. Schwarze J, Hamelmann E, Bradley KL et al. Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest 1997; 100: 226-33.
20. van Schaik SM, Enhorning G, Vargas I et al. Respiratory syncytial virus affects pulmonary function in BALB/c mice. J Infect Dis 1998; 177: 269-76.
21. Fonseca-Aten M, Rios AM, Mejias A et al. Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice. Am J Respir Cell Mol Biol 2005; 32: 201-10.
22. Ben-Mei C, Yi-Zeng L, Xiang C et al. Quantitative determination of azithromycin in human plasma by liquid chromatography-mass spectrometry and its application in a bioequivalence study. J Pharm Biomed Anal 2006; 42: 480-7.
23. Brewer E, Henion J. Atmospheric pressure ionization LC/MS/MS techniques for drug disposition studies. J Pharm Sci 1998; 87: 395-402.
24. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 2003; 47: 3973-5.
25. Cross JT, Jacobs RF. Other mycobacteria. In: Feigin RD, Cherry JD, Demmler GJ et al., eds. Textbook of Pediatric Infectious Diseases. Philadelphia: Saunders, 2004; 1379-88.
26. Bedos JP, Azoulay-Dupuis E, Vallee E et al. Individual efficacy of clarithromycin (A-56268) and its major human metabolite 14-hydroxy clarithromycin (A-62671) in experimental pneumococcal pneumonia in the mouse. J Antimicrob Chemother 1992; 29: 677-85.
27. Novelli A, Fallani S, Cassetta MI et al. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother 2002; 14: 584-90.
28. Li X, Atkinson TP, Hagood J et al. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J 2009; 28: 693-6.
29. Matsubara K, Morozumi M, Okada T et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother 2009; 15: 380-3.